Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects
Status:
Not yet recruiting
Trial end date:
2021-08-20
Target enrollment:
Participant gender:
Summary
This is a randomised, single-dose, subcutaneous injection, parallel study designed to compare
the PK of HLX14 and EU-sourced Prolia® in healthy Chinese adult male subjects, and to assess
the safety, tolerability, and immunogenicity of these 2 drugs.